- Organon launches ready to shop for women's health companies in biotech, medtech and more
- Merck-partnered Janux hires CMO as its bispecifics near clinic
- ASCO: Amgen's stomach cancer drug, nabbed in Five Prime buyout, extends patients' lives in phase 2
- ASCO: Novartis backs up $2.1B Endocyte buyout with prostate cancer data
- Stellanova, a 'new star' in the biotech constellation, hopes for bright future with $15.5M series A
- Sanofi inks partners for phase 3 pivotal trial of add-on breast cancer therapy
- China's Stemirna raises $188M to fund mRNA COVID-19 vaccine
- Ex-FDA deputy Abernethy lands at Verily, ready to steer clinical research
- It had to happen: Ex-Celgene shareholders sue Bristol Myers Squibb for $6.4B in lost CVR cash, claiming 'blatant misconduct'
- How new insights into skull-based immune cells could inspire treatments for brain disease
- Fierce Pharma Asia—Amgen-Kyowa Kirin eczema deal; J&J, Legend's CAR-T; CStone's PD-L1
- Chutes & Ladders—Repertoire Immune Medicines, buzzing from $189M series B, taps Celgene vet as CMO
Featured Story | By Annalee Armstrong Before Organon even launched, the new women’s health company spun out from Merck & Co. announced the acquisition of Alydia Health. On launch day yesterday, company executives put out a call for similarly minded companies to come under their wing. read more |
| |
|---|
|
|  | Webinar: Tenders for the Win - A Strategy to Secure Bids and Increase Revenue Thursday, June 17 | 10am ET / 7am PT Join our tender experts for a virtual session to learn strategies to optimize your bids, streamline processes, and improve collaboration and visibility across the tender lifecycle. You’ll also hear from Veronica Gil, Pricing & Tender Director, Baxter EMEA, on how her team leveraged technology to centralize processes and develop a winning tender strategy. Register Now. |
Top Stories By Nick Paul Taylor Janux Therapeutics has named Wayne Godfrey as its chief medical officer. Godfrey joins the Merck-partnered T-cell engager startup as it gears up to take candidates against PSMA, EGFR and TROP2 into the clinic. read more By Amirah Al Idrus Amgen battled other biopharma suitors for Five Prime Therapeutics early this year, emerging victorious in March with a $1.9 billion deal to snap up the cancer-focused biotech. Now, the company is painting a fuller picture for bemarituzumab, the crown jewel of the buyout, showing the treatment helped patients with advanced stomach cancer live longer. read more By Amirah Al Idrus Two years after splashing out $2.1 billion on Endocyte, Novartis is unveiling full phase 3 data for the radiopharmaceutical it picked up in that deal. The treatment, given alongside standard of care, added four months to the lives of patients with metastatic castration-resistant prostate cancer, helping them live a median of 15.3 months and reducing the risk of death by 38%. read more By Kyle LaHucik Stellanova Therapeutics now has fuel to get the “new star” on its journey to treating the tumor microenvironment. The Houston-based preclinical biotech has raised a $15.5 million series A led by Sporos Bioventures. The funding will go toward bringing Stellanova's lead antibody into the clinic, building out a discovery platform and growing the team, including leadership hires later this year. read more By Kyle LaHucik The French Big Pharma has landed partnerships with three groups to roll out a pivotal trial of its breast cancer hopeful amcenestrant as an add-on therapy, weeks after previewing promising early data at the American Society of Clinical Oncology meeting. read more By Nick Paul Taylor China’s Stemirna Therapeutics has raised RMB 1.2 billion ($188 million) to bankroll development of an mRNA vaccine against COVID-19. Sequoia Capital China co-led the financing with backers including WuXi AppTec plus assists from OrbiMed and other investors. read more By Andrea Park Amy Abernethy joins Verily shortly after her sudden departure from the FDA, where she had served as principal deputy commissioner of food and drugs for a little over two years—and where she was widely seen as a top contender for the agency’s (still-unfilled) top commissioner post. read more By Kevin Dunleavy When Bristol Myers Squibb failed to take a former Celgene drug past the FDA finish line, that company's shareholders lost out on a $6.4 billion contingency payment agreed as part of their megamerger. Investors railed—and Thursday, they sued. read more By Arlene Weintraub Researchers at Washington University discovered that some immune cells originate in the skull and migrate to the tissues that line the brain and spinal cord without passing through the bloodstream. Those immune cells shield the brain from disease and could inspire new treatments, they believe. read more By Angus Liu Amgen paid $400 million upfront to partner up with Kyowa Kirin on an atopic dermatitis candidate. Johnson & Johnson and Legend Biotech's CAR-T therapy scored a FDA priority review. CStone's PD-L1 inhibitor, with Pfizer and EQRx as partners, hit its phase 3 goal in non-small cell lung cancer. And more. read more By Fraiser Kansteiner Repertoire has added a former Celgene executive as its new chief medical officer. Renovacor, on the path to going public, has tapped a MyoKardia vet as its CMO. And Stellanova has taken off with a new founding CEO. read more Resources Sponsored by: Clinical Ink For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink. Sponsored by SDG Group Discover how Ashfield Healthcare uses the power of data and analytics to enable pre-call planning, inform sales rep actions and drive higher market share for its target pharmaceutical products. Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: Veeva One top 10 pharma outlines three key steps to launching a modular content strategy to generate localized content faster. Sponsored By: Blue Matter This 77-page e-book explores 7 keys to success that any biopharma company needs to keep in mind as it enters Europe. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
